The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Viccy Gibson paid just £70 for a month's supply of what she was told was semaglutide - the same ingredient used in ...

Walmart is joining Costco, Sam’s Club, and CVS in offering cheaper prices for customers paying out of pocket for Zepbound, ...

Chloe Brockett has claimed that taking the weight-loss jab Ozempic when she was a size 10 has left her with permanent vision ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy are holding back sales at the pharma ...

Weight loss drugs like Ozempic and Mounjaro could reshape food delivery habits, as users report eating smaller portions, ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agreed-on deal ...

People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their ...

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.